Page last updated: 2024-10-28

fasudil and Bladder Cancer

fasudil has been researched along with Bladder Cancer in 2 studies

fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Woldu, SL1
Hutchinson, RC1
Krabbe, LM1
Sanli, O1
Margulis, V1
Abe, H1
Kamai, T1
Hayashi, K1
Anzai, N1
Shirataki, H1
Mizuno, T1
Yamaguchi, Y1
Masuda, A1
Yuki, H1
Betsunoh, H1
Yashi, M1
Fukabori, Y1
Yoshida, K1

Reviews

1 review available for fasudil and Bladder Cancer

ArticleYear
The Rho GTPase signalling pathway in urothelial carcinoma.
    Nature reviews. Urology, 2018, Volume: 15, Issue:2

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Camellia sinensis; Carcinoma, Transitional Ce

2018

Other Studies

1 other study available for fasudil and Bladder Cancer

ArticleYear
The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells.
    BMC cancer, 2014, Jun-07, Volume: 14

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Prol

2014